European Journal of Medicinal Chemistry (2020)
Update date:2022-08-02
Topics:
Chen, Tao
Fang, Wei-Rong
Huang, Wei
Li, Yun-Man
Liu, Peng-Fei
Zhuo, Lin-Sheng
A series of 1,6-naphthyridinone-based MET kinase inhibitors bearing quinoline moiety in block A were designed and synthesized based on the structures of Cabozantinib and our reported compound IV. Extensive SAR and DMPK studies led to the identification of 20j, a potent and orally bioavailable MET kinase inhibitor with favorable kinase selectivity. More importantly, 20j exhibited statistically significant tumor growth inhibition (Tumor growth inhibition/TGI of 131%, 4/6 partial regression/PR) in the U-87 MG xeograft model, which is superior to that of Cabozantinib (TGI of 97%, 2/6 PR), and significantly better than that of compound IV (TGI of 15%, 0/6 PR) at the same dose (12.5 mg/kg). Combined with favorable in vitro potency, kinase selectivity, pharmacokinetic profile and in vivo efficacy, the promising antitumor drug candidate 20j has subsequently advanced into preclinical research.
View Moresuzhou BetterBioChem Co., Ltd.
website:http://www.betterbiochem.com
Contact:+86-18013506594
Address:No. 8 Building, 18 nong, Xi Yingnan Road, Pudong, Shanghai,China
Laizhou City Laiyu Chemical CO.,Ltd
Contact:+86-535-2719337/2719339
Address:Chenggang road zhuyou laizhou City Shangdong China
Sichuan Highlight Fine Chemicals Co., Ltd.
Contact:+86-28-8525 1605
Address:A5-102 Airport base,388 West Airport Huang He Zhong Lu,2 Section
Ji'nan Orgachem Pharmaceutical Co.,Ltd
Contact:+86-531-82687810
Address:Jinan
Refine Chemicals Science & Technology Technology Developing Co., Ltd.
Contact:+86-22-87899130
Address:No.12,west keyan road,Tianjin City
Doi:10.1080/00397911.2011.558969
(2012)Doi:10.1039/c2ob25990g
(2012)Doi:10.1021/jm00054a009
(1993)Doi:10.1021/jo00034a016
(1992)Doi:10.1021/jm00088a008
(1992)Doi:10.1021/ja00469a056
(1978)